<DOC>
	<DOCNO>NCT00031486</DOCNO>
	<brief_summary>This study involve patient 12 year old diagnose herpes simplex encephalitis ( HSE ) specific laboratory test complete treatment treat intravenous ( give needle inserted vein ) acyclovir . The purpose study determine treatment 4 tablet , 500 milligram , valacyclovir give 3 time daily mouth 90 day effective safe complete intravenous acyclovir treatment increase survival without mild impairment brain mental function . Participants assign either drug placebo ( inactive substance ) randomly ( chance ) . Study procedure include blood sample lumbar puncture ( procedure needle insert low back collect cerebral spinal fluid ) . Subjects participate 24 month .</brief_summary>
	<brief_title>Long Term Treatment Herpes Simplex Encephalitis ( HSE ) With Valacyclovir</brief_title>
	<detailed_description>Herpes simplex encephalitis ( HSE ) remain common cause sporadic fatal encephalitis world . This study phase III , double-blind , placebo control study long term therapy valacyclovir treatment herpes encephalitis . The primary objective study assess impact valacyclovir ( VACV ) therapy ( follow standard intravenous acyclovir therapy ) neuropsychological impairment one year post therapy , base cumulative score Mattis Dementia Rating Scale ( MDRS ) . The secondary objective study : assess effect therapy neuropsychological impairment various time point ; assess effect therapy quality life , base SF-36 Quality Life Assessment ; measure effect therapy herpes simplex virus ( HSV ) deoxyribonucleic acid ( DNA ) cerebral spinal fluid ( CSF ) ; assess safety tolerability long term VACV therapy patient HSE . The tertiary objective study determine frequency symptomatic relapse/recurrence HSE . Study participant include 120 male female , 12 year age old , diagnosed HSE ; laboratory confirm CSF positive HSV DNA polymerase chain reaction ( PCR ) . Consenting study participant randomize ( 1:1 ) either valacyclovir ( active drug ) , 500 mg tablet , four tablet three time daily 90 day placebo ( identical active drug appearance ) , 500 mg tablet , four tablet three time daily 90 day . The primary endpoint study assess impact valacyclovir therapy [ follow standard intravenous acyclovir ( ACV ) therapy ] neuropsychological impairment one year post therapy survival mild neuropsychological impairment 12 month initiation study medication , measure MDRS . The secondary endpoint include : survival mild neuropsychological impairment 90 day 6 , 12 24 month , measure MDRS , Mini-Mental Status Examination ( MMSE ) , Glasgow Coma Scale ; effect study medication quality life measurement ; effect antiviral therapy HSV DNA CSF ( measure quantitatively PCR Day 0 Day 90 ) ; safety tolerance VACV administer dose 2.0 gram give orally three time day 90 day . Each study participant participate approximately 24 month .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Encephalitis , Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Informed consent and/or assent must obtain patient legal guardian . Patients encephalopathy consistent herpes simplex encephalitis ( HSE ) whose cerebral spinal fluid ( brain biopsy sample ) positive herpes simplex virus ( HSV ) deoxyribonucleic acid ( DNA ) polymerase chain reaction ( PCR ) . Patients receive complete intravenous ( IV ) acyclovir ( ACV ) therapy minimum duration 14 day maximum 21 day minimum dose 30 mg/kg/day maximum 60 mg/kg/day , equivalent dose adjust renal dysfunction . Patient expect available followup visit study drug administration 24 month study visit . Patients 12 year age old . Patients weigh great equal 45.5kg ( 100 pound ) . All female patient childbearing potential must negative pregnancy test within 72 hour prior initiation study drug . If pregnancy test positive , patient ineligible study . Women must postmenopausal , surgically sterile willing use adequate contraception ( barrier method spermicide , intrauterine device ( IUD ) , oral contraceptive , implant license hormone method ) time study enrollment 1 month last dose study treatment . Men must surgically sterile willing use contraception ( barrier method spermicide ) time study enrollment 1 month last dose study treatment . Patients herpes simplex virus ( HSV ) meningitis , without evidence HSV encephalitis . Patients anticipated life expectancy &lt; 90 day . Patients creatinine clearance less equal 50ml/min./1.73 m^2 . Pregnant breastfeeding female . Patients receive antiherpesvirus medication ( e.g . ganciclovir ) intravenous acyclovir ( ACV ) acute therapy current episode herpes simplex encephalitis ( HSE ) . Patients unable swallow oral medication time study drug randomization ( Day 0 ) . Patients &gt; 3 day beyond completion treatment course intravenous ( IV ) ACV . Patients expect receive longterm ( &gt; 30 days/year ) therapy antiviral medication active HSV [ e.g . ACV , valacyclovir ( VACV ) , famciclovir ] .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>encephalitis , herpes simplex , valacyclovir</keyword>
</DOC>